Parkinson's disease: Aetiology, diagnosis, and management

Hong Kong Medical Journal

Volumn 11, Issue 6, 2005, Pages 476-489

  Leung, H ^a   Mok, V ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chinese; Hong Kong; Parkinson disease

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; ADENOSINE A2 RECEPTOR; ALPHA TOCOPHEROL; AMANTADINE; APOMORPHINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOT DERIVATIVE; GABAERGIC RECEPTOR AFFECTING AGENT; LEVODOPA; LISURIDE; LISURIDE MALEATE; MINOCYCLINE; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PERGOLIDE MESILATE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

BLURRED VISION; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DATA ANALYSIS; DEMENTIA; DIZZINESS; DOPAMINERGIC TRANSMISSION; DYSKINESIA; FAMILIAL DISEASE; GENETIC SUSCEPTIBILITY; GENETICS; HALLUCINATION; HUMAN; HYPOTENSION; INSOMNIA; LIVER TOXICITY; MEDICAL RESEARCH; MEDLINE; MOTOR DYSFUNCTION; NAUSEA; NEUROIMAGING; NEUROPROTECTION; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PREVALENCE; RATING SCALE; REVIEW; SCIENTIFIC LITERATURE; SKIN DEFECT; SYMPTOM; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANTIPARKINSON AGENTS; HONG KONG; HUMANS; PARKINSON DISEASE; PREVALENCE;

EID: 30944434400     PISSN: 10242708     EISSN: 10242708     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Maher NE, Golbe LI, Lazzarini AM, et al. Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology 2002;58:79-84.
2. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.
3. McInerney-Leo A, Hadley DW, Gwinn-Hardy K, Hardy J. Genetic testing in Parkinson's disease. Mov Disord 2005;20:1-10.
4. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002;58:179-85.
5. Chan DK, Mellick G, Cai H, et al. The alpha-synuclein gene and Parkinson disease in a Chinese population. Arch Neurol 2000;57:501-3.
6. Lu CS, Wu JC, Tsai CH, et al. Clinical and genetic studies on familial parkinsonism: the first report on a parkin gene mutation in a Taiwanese family. Mov Disord 2001;16: 164-6.
7. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-7.
8. Tan EK, Chan DK, Ng PW, et al. Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 2005;62:460-4.
9. Chan DK, Lam MK, Wong R, Hung WT, Wilcken DE. Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology 2003;60:1002-5.
10. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583-8.
11. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989;39:660-4.
12. Chan DK, Cordato D, Bui T, Mellick G, Woo J. Comparison of environmental and genetic factors for Parkinson's disease between Chinese and Caucasians. Neuroepidemiology 2004;23:13-22.
13. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.
14. Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 2002;9(Suppl 3):7S-14S.
15. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195-208.
16. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology 1989;39:1314-8.
17. Woo J, Lau E, Ziea E, Chan DK. Prevalence of Parkinson's disease in a Chinese population. Acta Neurol Scand 2004;109:228-31.
18. Tan LC, Venketasubramanian N, Hong CY, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 2004;62:1999-2004.
19. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
20. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-9.
21. Yeung JH; The Hong Kong Parkinson's Disease Registry Study Group. The Hong Kong Parkinson's Disease Registry: A multi-centre study of clinical and treatment profiles of ethnic Chinese patients using strict diagnostic criteria. Mov Disord 2004;19(Suppl 9):129S.
22. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93-101.
23. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000;284:1931-8.
24. Oertel W. Pergolide vs 1-dopa (PELMOPET). Mov Disord 2001;15(Suppl 3):5S.
25. Fahn S, Elton RL. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park: Macmillan Healthcare Information; 1987: 153-63.
26. Schwab RS, England Jr AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gilingham FJ, Donaldson IML, editors. Third symposium on Parkinson's disease. Edinburgh: E & S Livingstone; 1969:152-7.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
28. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993;328:176-83.
29. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol 1998;43:318-25.
30. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001;56:1712-21.
31. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-43.
32. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
33. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des 2004;10:679-86.
34. Jankovic J, Hunter C. A double-blind placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002;8:271-6.
35. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(Suppl 4):1S-166S.
36. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(11 Suppl 5):1S-88S.
37. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999;56:529-35.
38. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-508.
39. Poewe WH. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology 1994;44(7 Suppl 6):6S-9S.
40. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64.
41. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-7.
42. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediaterelease and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53:1012-9.
43. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 1999;22:351-5.
44. Ramaker C, van Hilten JJ. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev 2000;(3):CD002258.
45. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, Barbanoj M, Gironell A, Pascual-Sedano B. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol 1998;21:358-62.
46. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999;53:573-9.
47. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;33:1009-14.
48. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9:431-6.
49. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45 (3 Supp 3):13S-21S.
50. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl 1995;45: 225-30.
51. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-8.
52. Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998;5:235-42.
53. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999;66:436-41.
54. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 2003;18:1149-56.
55. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997;49:724-8.
56. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72:713-20.
57. Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci 2003;216:81-7.
58. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F; 043 Study Group. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002;109:489-502.
59. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998;21:101-7.
60. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-9.
61. Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J Neurol 2003;250:90-6.
62. Mungersdorf M, Sommer U, Sommer M, Reichmann H. High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm 2001;108:1309-17.
63. Clarke CE, Deane KH. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000;(3):CD001517.
64. Schrag A, Keens J, Warner J; Ropinirole Study Group. Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol 2002;9:253-7.
65. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999;53:364-70.
66. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-8.
67. Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001;(1):CD001519.
68. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-7.
69. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev 2000;(2):CD000236.
70. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-5.
71. Clarke CE, Speller JM, Clarke JA. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000;(3):CD002259.
72. Pinter MM, Rutgers AW, Hebenstreit E. An open-label, multicentre clinical trial to determine the levodopa dosesparing capacity of pramipexole in patients with idiopathic Parkinson's disease. J Neural Transm 2000;107:1307-23.
73. Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003;26:146-50.
74. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-62.
75. Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebocontrolled study. Mov Disord 2001;16:459-63.
76. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001;24:163-9.
77. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55 (Suppl 1):23S-30S.
78. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45.
79. van Hilten JJ, Ramaker C, Van de Beek WJ, Finken MJ. Bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev 2000; 2:CD001203.
80. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003;16(Suppl 1):13S-19S.
81. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-4.
82. Agarwal P, Fahn S, Frucht SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2004;19: 699-704.
83. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83.
84. Entacapone improves motor fluctuations in levodopatreated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997;42:747-55.
85. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-14.
86. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M; NOMESAFE Study Group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003;10:137-46.
87. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;(2):CD003735.
88. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-8.
89. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-6.
90. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-6.
91. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 2004;19:743-54.
92. Braz L, Borges V, Ferraz H. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind placebo-controlled pilot study. Clin Neuropharmacol 2004;27:25-9.
93. Chan DT, Mok VC, Poon WS, Hung KN, Zhu XL. Surgical management of Parkinson's disease: a critical review. Hong Kong Med J 2001;7:34-9.
94. Mok V. Deep brain stimulation for management of Parkinson's disease. Hong Kong Med J 2001;7(Suppl):13S.
95. Macia F, Perlemoine C, Coman I, et al. Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 2004;19:206-12.
96. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-9.
97. Dewey RB Jr. Management of motor complications in Parkinson's disease. Neurology 2004;62(6 Suppl 4):3S-7S.
98. Chaudhuri KR. Nocturnal symptom complex in PD and its management. Neurology 2003;61(6 Suppl 3):17S-23S.
99. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708-12.
100. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003;108:368-73.
101. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.
102. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-63.
103. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2.
104. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55: 789-94.
105. Gimenez-Roldan S, Navarro E, Mateo D. Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease [in Spanish]. Rev Neurol 2003;36:401-4.
106. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19:29-35.
107. Mancini F, Tassorelli C, Martignoni E, et al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin Neuropharmacol 2004;27:33-7.
108. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov Disord 2000;15:1269-71.
109. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997; 277:1046-51.